Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PYGB | P11216 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626821 | 1.00 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL5579411 | 1.00 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL28558171 | 1.00 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL5579412 | 1.00 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15679244 | 1.00 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL23848860 | 0.88 | LGALS1 (0.35) | ALDH1A1TSHRLMNATDP1PYGB | |
| SCHEMBL263940 | 0.81 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12799380 | 0.81 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL7603707 | 0.81 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12899874 | 0.81 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-10577359-B2 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | GILEAD PHARMASSET LLC (US) | 2020-03-03 | — | — | US | disclosed |
| EP-1809301-B1 | 2-FLUORO-2-ALKYL-SUBSTITUTED D-RIBONOLACTONE INTERMEDIATES | GILEAD PHARMASSET LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-1809301-B1 | 2-FLUORO-2-ALKYL-SUBSTITUTED D-RIBONOLACTONE INTERMEDIATES | GILEAD PHARMASSET LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20170253584-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | GILEAD PHARMASSET LLC (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2017077552-A1 | PROCESS FOR THE PREPARATION OF SOFOSBUVIR | MYLAN LABORATORIES LIMITED (IN) | 2017-05-11 | — | — | WO | disclosed |
| EP-3109244-A2 | PREPARATION OF 2'FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | Gilead Pharmasset LLC (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016035006-A1 | NOVEL NUCLEOTIDE ANALOGS, PROCESS FOR THE PREPARATION OF SOFOSBUVIR AND ITS ANALOGS, NOVEL FORMS OF SOFOSBUVIR AND SOLID DISPERSION OF SOFOSBUVIR | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016035006-A1 | NOVEL NUCLEOTIDE ANALOGS, PROCESS FOR THE PREPARATION OF SOFOSBUVIR AND ITS ANALOGS, NOVEL FORMS OF SOFOSBUVIR AND SOLID DISPERSION OF SOFOSBUVIR | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016016446-A1 | PROCESS FOR PREPARING 2-FLUOROPROPIONALDEHYDE | SANDOZ AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| US-20160024061-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | PHARMASSET, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20130338349-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | PHARMASSET, INC. | 2013-12-19 | — | — | US | disclosed |
| US-8492539-B2 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | GILEAD PHARMASSET LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
| EP-1809301-A2 | PREPARATION OF 2'FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | Pharmasset, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060122146-A1 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006031725-A2 | PREPARATION OF 2'FLUORO-2'- ALKYL- SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | PHARMASSET, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024061-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | NSUN2, FBL, RNGTT | CDA 30/4885PDE4D 1817/4885PDE3A 2509/4885 |
| US-20170253584-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | NSUN2, FBL, RNGTT | CDA 31/4885PDE4D 1834/4885PDE3A 2441/4885 |
| US-10577359-B2 | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | NSUN2, FBL, RNGTT | CDA 29/4885PDE4D 1811/4885PDE3A 2416/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | CDA 95/4885PDE4D 157/4885PDE3A 725/4885 |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | CDA 33/4885PDE4D 493/4885PDE3A 1521/4885 |
| US-20060122146-A1 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | NSUN2, FBL, RNGTT | CDA 31/4885PDE4D 1834/4885PDE3A 2441/4885 |
| US-20130338349-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | NSUN2, FBL, RNGTT | CDA 31/4885PDE4D 1834/4885PDE3A 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.